Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06435195
Other study ID # K5112
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date December 2026

Study information

Verified date May 2024
Source Peking Union Medical College Hospital
Contact Yong Yao, MD
Phone +8669152530
Email yaoyong@pumch.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to systematically describe the clinical characteristics and outcomes of patients with pituitary complex and rare diseases at Peking Union Medical College Hospital. The main questions it aims to answer are: - What are the influencing factors and rates of remission? - What are the comorbidities associated with these diseases? - What are the perioperative events, radiological findings, and pathological features? Researchers will compare different patient groups to see if there are significant differences in these outcomes. Participants will: - Undergo detailed clinical evaluations. - Provide medical history and data for analysis. - Participate in follow-up assessments to monitor disease progression and treatment outcomes.


Description:

The study aims to provide a comprehensive analysis of pituitary complex and rare diseases at Peking Union Medical College Hospital. By leveraging a large cohort, the research will explore various clinical characteristics and outcomes. Specifically, the study will examine influencing factors and rates of remission, the presence of comorbidities, and perioperative events. Additionally, it will evaluate radiological findings and pathological features to better understand these conditions. Through this detailed investigation, the study seeks to enhance knowledge and inform clinical practice regarding the management and prognosis of pituitary complex and rare diseases.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date December 2026
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Diagnosed with rare sellar diseases including but not limited to pituitary adenomas (such as Thyrotropin-secreting pituitary adenomas, GH-secreting adenomas), craniopharyngiomas, Rathke's cleft cysts, sellar region germ cell tumors, cavernous sinus syndrome, and other diseases - Detailed medical history, including clinical symptoms, treatment plans and follow-up outcomes Exclusion Criteria: - Incomplete medical records, especially missing key imaging diagnostic results - Patients with coexisting primary central nervous system diseases unrelated to sellar region diseases (such as severe traumatic brain injury) - Patients whose sellar region pathological diagnosis was changed or overturned during the follow-up period

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Surgical Removal
Resection of pituitary pathologies.
Biopsy
Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Remission Hormonal normalization and free of pathologies Postoperative one week and extends to the latest follow-up, estimated at up to 3 years
Secondary Disease Comorbidities Systemic changes accompanied with Pituitary Complex and Rare Diseases From patient admission to an evaluation period extending up to the latest follow-up, estimately up to 3 years
Secondary Postoperative complications adverse events or medical issues that arise after a surgical procedure on the pituitary diseases.These complications can include various problems such as bleeding, infection, hormonal imbalances, cerebrospinal fluid leaks, vision changes, or neurological deficits Postoperative one week and extends to the latest follow-up, estimated at up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04897802 - Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) Phase 4
Completed NCT03137615 - The Cardiovascular Changes Associated With Septal Local Anaesthesia N/A
Completed NCT03305016 - A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency Phase 3
Completed NCT02084134 - Peri-Operative Steroid Management in Patients N/A
Completed NCT00234533 - Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Phase 3
Completed NCT04902235 - Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study) Phase 4
Recruiting NCT04951557 - Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas
Active, not recruiting NCT00473369 - Prognosis of Atypical Pituitary Adenomas N/A
Active, not recruiting NCT03665064 - Long Term Outcome Study in Patients With Pituitary Disorders
Completed NCT02782208 - Lipolytic Effects of GH in Hypopituitary Patients in Vivo N/A
Recruiting NCT04326374 - Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency Phase 3
Completed NCT03344458 - A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial Phase 3
Completed NCT02781727 - A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Phase 3